loader
Page is loading...
Print Logo Logo
medical research


SPEAKERS

Christopher Bayh

Christopher J. Bayh

Partner
Higher Education Practice Co-Chair
Deborah Pollack Milgate

Deborah Pollack-Milgate

Partner
Vice-Chair of the European Practice Group
Joseph Allen

Joseph Allen

Executive Director
Bayh-Dole Coalition
Kristin Jones

Kristin Jones

President and CEO
Indiana Health Industry Forum



SPEAKERS

Christopher Bayh

Christopher J. Bayh

Partner
Higher Education Practice Co-Chair
Deborah Pollack Milgate

Deborah Pollack-Milgate

Partner
Vice-Chair of the European Practice Group
Joseph Allen

Joseph Allen

Executive Director
Bayh-Dole Coalition
Kristin Jones

Kristin Jones

President and CEO
Indiana Health Industry Forum

Late in 2023, the White House released draft guidance outlining proposed factors that an agency may consider, including the “reasonableness of a product’s price,” when deciding whether to exercise its “march-in rights” to federally funded inventions under the Bayh-Dole Act.

This would be an unprecedented step and the legislation was never intended to be used this way. According to key stakeholders, this will negatively affect innovation across the spectrum of life sciences – from universities and federal R&D labs, to startups, big pharma, investors, and ultimately patients.

Please join us as we explore the impact of the Bayh-Dole Act on the life sciences sector and what this threat may mean for companies going forward.

Networking and lunch begins at 11:30 a.m. and the program begins at noon.

There will not be a Zoom option for this session.

Questions? Email Blakelee Kortz or call 317-231-7316.

RELATED ARTICLES

    RELATED OFFICES

  • BT Law Firm Indianapolis Indiana

    Indianapolis

    P 317-236-1313 F 317-231-7433
Trending Connect
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to use cookies.